Journal: bioRxiv
Article Title: A connexin 43 targeting peptide prevents blood vessel neointima formation
doi: 10.1101/2025.09.22.677165
Figure Lengend Snippet: 5-ethynyl-2’-deoxyuridine (EDU) proliferation assay in human coronary artery smooth muscle cells (CASMC; A ). Schematic showing the design for bulk RNA sequencing and group combinations for analysis ( B ). Principal component analysis (PCA) of ‘DESeq2’ normalized and log 2 transformed counts ( C ). Volcano plots of ‘DESeq2’ differentially expressed genes (DEGs) identified with |log 2 (Fold Change (FC))| > 0 and an adjusted p-value (padj) < 0.05 for indicated group comparisons ( D ). Venn diagram of the total number of identified DEGs unique to and shared by the PDGF-β (PD) + Off Target Peptide (OT) and PD + CycliCx peptide treatment groups when compared to PD treatment alone ( E ). Top 10 pathways by padj from Gene Ontology (GO) Biological Process pathway analysis ranked by gene ratio (left panel shows top 10 upregulated pathways in PD vs no treatment (NT) and right panel shows top 10 downregulated pathways in PD + CycliCx vs PD + OT; F ). Heatmap of between replicate ‘DESeq2’ normalized gene expression z-scores for PD + CycliCx vs PD + OT DEGs from the significantly enriched GO pathway GO:0000082: ‘cell cycle G1/S phase transition ( G ). ‘DESeq2’ normalized gene counts in selected genes ( H ). N = 3-4 per group. Data displayed as mean ± SEM. P-values calculated by Tukey’s multiple comparison testing after one-way ANOVA.
Article Snippet: Euclidean distances were then calculated and principal component analysis (PCA) was performed using ‘dist()’ and ‘prcomp()’, respectively, in base R. Differential gene expression analysis was performed by Novogene for every possible combination of sample groups using ‘DESeq2’ (v.1.20.0) with Benjamini-Hochberg multiple comparison adjustment.
Techniques: Proliferation Assay, RNA Sequencing, Transformation Assay, Gene Expression, Sublimation, Comparison
